2016
DOI: 10.2174/0929867323666160321121138
|View full text |Cite
|
Sign up to set email alerts
|

Why Antidiabetic Vanadium Complexes are Not in the Pipeline of “Big Pharma” Drug Research? A Critical Review

Abstract: Public academic research sites, private institutions as well as small companies have made substantial contributions to the ongoing development of antidiabetic vanadium compounds. But why is this endeavor not echoed by the globally operating pharmaceutical companies, also known as “Big Pharma”? Intriguingly, today’s clinical practice is in great need to improve or replace insulin treatment against Diabetes Mellitus (DM). Insulin is the mainstay therapeutically and economically. So, why do those companies develo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
41
0
4

Year Published

2017
2017
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 88 publications
(45 citation statements)
references
References 129 publications
(143 reference statements)
0
41
0
4
Order By: Relevance
“…However, due to kidney problems in some patients, BEOV as an antidiabetic agent could not progress to the next phase of research. Indeed, the risks associated with vanadium intoxication such as vanadium-induced reactive oxygen species generation, adverse effects on the immune system, and a risk of mutagenesis are listed among the arguments against the antidiabetic application of vanadium [42]. Domingo and Gomez [43] reviewed the results of past and [44,45].…”
Section: Overview Of Vanadiummentioning
confidence: 99%
“…However, due to kidney problems in some patients, BEOV as an antidiabetic agent could not progress to the next phase of research. Indeed, the risks associated with vanadium intoxication such as vanadium-induced reactive oxygen species generation, adverse effects on the immune system, and a risk of mutagenesis are listed among the arguments against the antidiabetic application of vanadium [42]. Domingo and Gomez [43] reviewed the results of past and [44,45].…”
Section: Overview Of Vanadiummentioning
confidence: 99%
“…This inhibition focused interest in enhanced insulin signaling and associated anti‐diabetic activities, but the focus has since shifted towards anti‐cancer, anti‐parasitic and tissue regeneration (e.g, cardio‐ and neuroprotective) properties of V drugs. Clinical trials of oral anti‐diabetic V drugs were abandoned due to low stability in gastrointestinal media and unfavorable pharmacokinetics, but consumption of V nutritional supplements is still widespread …”
Section: Vanadium Complexes As Pro‐drugsmentioning
confidence: 99%
“…Thus, it is possible to consider a new prodrug concept that implies dissociation of vanadium complexes before they reach the target biomolecules [ 44 ]. In this regard, decavanadate species are usually not considered in vanadium toxicological studies, mainly by speciation of vanadyl (V IV O) 2+ or vanadate (V V O 4 ) 3− [ 45 ].…”
Section: Discussionmentioning
confidence: 99%